FTC (US Federal Trade Commission) approves AmeriPath sale, shareholders rebel:
This article was originally published in Clinica
Executive Summary
The US Federal Trade Commission has given antitrust clearance to the acquisition of genomic and cancer diagnostic services group AmeriPath by buy-out firm Welsh Carson Anderson & Stowe. WCAS unit Amy Acquisition is offering $21.25 per share in cash and to assume $172m of debt. Shareholders with a combined stake of about 4.5% have filed a lawsuit against the firm's directors on the grounds that the price is too low and not in shareholders' interests. AmeriPath's share is currently trading at $21.60; it was selling for $16.45 immediately before the offer was made in December.